Unihealth Hospitals Ltd

- The company has successfully completed an IPO and listing on NSE Emerge in September 2023, which has already facilitated significant growth. - The board has approved extending debt to its subsidiary, Unihealth Pharmaceuticals Private Limited, to support increased export and distribution activities. - There is no explicit mention of any new upcoming fundraising through equity or external debt beyond this approved debt extension to the subsidiary. - The company is focusing on organic growth, acquisitions, and an asset-light model by leveraging existing infrastructure for expansion. - Capex for the next two years is planned at around INR 25 crores, primarily for equipment investments rather than infrastructure. - Overall, current plans rely on internal accruals, subsidiary debt, and strategic partnerships, with no fresh equity or large debt fundraising announced.

- Current capex plan: INR 25 crores (~INR 2,500 lakhs) over the next two years, mainly for investing in high-end medical equipment rather than infrastructure, following an asset-light model. - Focus on expanding bed capacity from 200 to 1000 beds by FY 2025-26, including 300-350 beds targeted in India (Western India) through organic growth and acquisitions. - Expansion involves upgrading existing hospitals in Uganda and Nigeria with super specialty services (ophthalmology, infertility, cardiology) by investing in equipment and specialized manpower. - Acquisition strategy: Targeting 50-100 bed facilities, combined with operating and management (O&M) contracts leveraging existing local infrastructure. - Pharmaceutical division capex involves registering manufacturing plants and drugs in African countries to increase export and distribution, with approvals expected in 9 to 15 months. - Strategic investment in medical travel collaborations with airlines (e.g., Ethiopian Air, Air Tanzania, Myanmar Airways) to boost patient inflow.

- Target to increase bed capacity from current 200 beds to around 1,000 beds by FY 2025-26, including 300-350 beds in India. - Expansion plans include both organic growth (O&M contracts) and acquisitions, focusing on 50-100 bed facilities. - Expect significant revenue growth from adding super specialty services like ophthalmology, infertility, cardiology, and later cancer care. - Pharmaceutical product registrations underway; expect multi-fold growth in pharmaceutical exports and sales post-registration by 2025-26. - New syringe manufacturing plant in Tanzania to commission by June next year, targeting 5-6 million syringes per month with potential to add infusion sets and other consumables. - Increasing distribution to government agencies and NGOs in African countries, expanding beyond captive use. - Overall, steady volume and revenue growth expected from both hospital expansion and diversified product offerings in India and Africa.

- The company targets increasing bed capacity from 200 to 1,000 beds by fiscal year 2025-26, including 300-350 beds in India, which will drive revenue growth. - Expansion involves both organic growth (new setups, O&M contracts) and acquisitions (50-100 bed facilities). - Investment focus is on equipment and super specialty services (ophthalmology, infertility, cardiology) to enhance EBITDA margins. - Overseas business currently contributes over 90% to revenue and profitability; growth in African markets is a priority. - Pharmaceutical product registrations underway; once completed (~9-15 months), this will significantly boost revenue. - Brand recognition is strong in Africa, with increasing brand presence planned in India. - Operating cash flows are solid, supporting capex plans of INR 25 crores over two years. - Expected increase in specialty services and hospital capacities will likely lead to multi-fold revenue and profit expansion.

- The transcript on page 17 does not explicitly mention the current or expected order book or pending orders in specific numbers. - However, it highlights ongoing and future business opportunities in Uganda, Nigeria, and Tanzania, including: - Distribution and sales of imported medical goods to government agencies, UN, and other medical centers. - Participation in government and NGO tenders in targeted countries once product registrations are completed, leading to potential multi-fold business increase. - Expansion plans include targeting 300+ bed capacity in India with hospital bids, though no condition of exclusivity as consultant. - The company is pursuing both organic growth and acquisitions to increase bed capacity from 200 to 1000 by 2026. - Investment in equipment and super specialty services in existing African facilities is ongoing. - No specific numeric order book or pending order values are disclosed in the available transcript pages.